RETRACTED ARTICLE: HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis

Huang, Pinbo; Xu, Qingdong; Yan, Yongcong; Lu, Yaobin; Hu, Zhigang; Ou, Bing; Zhang, Heyun; Mao, Kai; Zhang, Jianlong; Wang, Jie; Xiao, Zhiyu

doi:10.1038/s41388-020-1254-z

Cited by 33 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The key viral protein HBx is a multifunctional oncoprotein that modulates transcription, signal transduction, cell cycle progression, apoptosis, protein degradation and genetic stability through interactions with host factors [5,51]. We previously discovered that HBx causes resistance to bortezomib via MEK signaling [5] and regulates the LINC01352-miR-135b-APC axis in tumor progression in HCC [6]. Here, we found that HBx downregulated PTPN13 expression in hepatoma cells.…”

Section: Discussionmentioning

confidence: 75%

“…HBV factors, including the hepatitis B x protein (HBx), the pre-S2/S gene and the HBV-spliced protein, have been implicated in liver cancer progression [5]. HBx, a well-known oncogenic protein in HBVrelated hepatocarcinogenesis, modulates the expression of important genes and affects the cytoplasmic modulation of signal transduction pathways [6,7]. Metabolic reprogramming is a selective advantage that supports cancer cell biosynthetic needs, rapid proliferation and tumor growth [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression

et al. 2020

Self Cite

View full text Add to dashboard Cite

Hepatitis B x protein (HBx) affects cellular protein expression and participates in the tumorigenesis and progression of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Metabolic reprogramming contributed to the HCC development, but its role in HBV-related HCC remains largely unclear. Tyrosine-protein phosphatase nonreceptor type 13 (PTPN13) is a significant regulator in tumor development, however, its specific role in hepatocarcinogenesis remains to be explored. Here, we found that decreased PTPN13 expression was associated with HBV/HBx. Patients with low PTPN13 expression showed a poor prognosis. Functional assays revealed that PTPN13 inhibited proliferation and tumorigenesis in vitro and in vivo. Further mechanistic studies indicated that HBx inhibited PTPN13 expression by upregulating the expression of DNMT3A and interacting with DNMT3A. Furthermore, we found that DNMT3A bound to the PTPN13 promoter (−343 to −313 bp) in an epigenetically controlled manner associated with elevated DNA methylation and then inhibited PTPN13 transcription. In addition, we identified IGF2BP1 as a novel PTPN13-interacting gene and demonstrated that PTPN13 influences c-Myc expression by directly and competitively binding to IGF2BP1 to decrease the intracellular concentration of functional IGF2BP1. Overexpressing PTPN13 promoted c-Myc mRNA degradation independent of the protein tyrosine phosphatase (PTP) activity of PTPN13. Importantly, we discovered that the PTPN13-IGF2BP1-c-Myc axis was important for cancer cell growth through promoting metabolic reprogramming. We verified the significant negative correlations between PTPN13 expression and c-Myc, PSPH, and SLC7A1 expression in clinical HCC tissue samples. In summary, our findings demonstrate that PTPN13 is a novel regulator of HBV-related hepatocarcinogenesis and may play an important role in HCC. PTPN13 may serve as a prognostic marker and therapeutic target in HBV-related HCC patients.

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although there is little evidence of direct association of LINC01352, PGM5-AS1, and SATB2-AS1 with LUAD, many studies have shown that they play a key role in different tumors. Pinbo Huang et al found that HBV/HBx (HBV X protein) complex can reduce the expression level of LINC01352 which in turn inhibits LINC01352-miR-135b-APC axis and promotes the development of HCC.LINC01352 is an independent prognostic molecule for HCC (65). PGM5-AS1 has different effects in different tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Pinbo Huang et al. found that HBV/HBx (HBV X protein) complex can reduce the expression level of LINC01352 which in turn inhibits LINC01352-miR-135b-APC axis and promotes the development of HCC.LINC01352 is an independent prognostic molecule for HCC ( 65 ). PGM5-AS1 has different effects in different tumors.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma

Liu

Zhao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is a highly heterogeneous malignancy, which makes prognosis prediction of LUAD very challenging. Ferroptosis is an iron-dependent cell death mechanism that is important in the survival of tumor cells. Long non-coding RNAs (lncRNAs) are considered to be key regulators of LUAD development and are involved in ferroptosis of tumor cells, and ferroptosis-related lncRNAs have gradually emerged as new targets for LUAD treatment and prognosis. It is essential to determine the prognostic value of ferroptosis-related lncRNAs in LUAD. In this study, we obtained RNA sequencing (RNA-seq) data and corresponding clinical information of LUAD patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database and ferroptosis-related lncRNAs by co-expression analysis. The best predictors associated with LUAD prognosis, including C5orf64, LINC01800, LINC00968, LINC01352, PGM5-AS1, LINC02097, DEPDC1-AS1, WWC2-AS2, SATB2-AS1, LINC00628, LINC01537, LMO7DN, were identified by Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis, and the LUAD risk prediction model was successfully constructed. Kaplan-Meier analysis, receiver operating characteristic (ROC) time curve analysis and univariate and multivariate Cox regression analysis and further demonstrated that the model has excellent robustness and predictive ability. Further, based on the risk prediction model, functional enrichment analysis revealed that 12 prognostic indicators involved a variety of cellular functions and signaling pathways, and the immune status was different in the high-risk and low-risk groups. In conclusion, a risk model of 12 ferroptosis related lncRNAs has important prognostic value for LUAD and may be ferroptosis-related therapeutic targets in the clinic.

show abstract

“…LIHC is a major malignant and lethal tumour that is the most common in Asian patients with chronic hepatitis B virus (HBV) infection [ 61 , 62 ]. The HBV genome encodes DNA polymerase, surface antigen, core protein and HB X [ 63 ].…”

Section: Rsf1 Interacts With Hb X and Bubr1 To Recruit Hb X To The Kinetochore To Decrease The Bubrmentioning

confidence: 99%

RSF1 in cancer: interactions and functions

2021

View full text Add to dashboard Cite

RSF1, remodelling and spacing factor 1, is an important interphase centromere protein and is overexpressed in many types of cancers and correlated with poor overall survival. RSF1 has functions mainly in maintaining chromosome stability, facilitating DNA repair, maintaining the protein homeostasis of RSF1 and suppressing the transcription of some oncogenes when RSF1 protein is expressed at an optimal level; however, RSF1 overexpression facilitates drug resistance and cell cycle checkpoint inhibition to prompt cancer proliferation and survival. The RSF1 expression level and gene background are crucial for RSF1 functions, which may explain why RSF1 has different functions in different cancer types. This review summarizes the functional domains of RSF1, the overexpression status of RSF1 and SNF2H in cancer based on the TCGA and GTEX databases, the cancer-related functions of RSF1 in interacting with H2Aub, HDAC1, CENP-A, PLK1, ATM, CENP-S, SNF2H, HBX, BubR1, cyclin E1, CBP and NF-κB and the potential clinical value of RSF1, which will lay a theoretical foundation for the structural biology study of RSF1 and application of RSF1 inhibitors, truncated RSF1 proteins and SNF2H inhibitors in the treatment of RSF1-overexpressing tumours.

show abstract

RETRACTED ARTICLE: HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis

Cited by 33 publications

References 41 publications

Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression

Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression

Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma

RSF1 in cancer: interactions and functions

Contact Info

Product

Resources

About